Proteome‐Wide Mendelian Randomization Analysis Identified Potential Drug Targets for Atrial Fibrillation

BACKGROUND: Finding effective and safe therapeutic drugs for atrial fibrillation (AF) is an important concern for clinicians. Proteome‐wide Mendelian randomization analysis provides new ideas for finding potential drug targets. METHODS AND RESULTS: Using a proteome‐wide Mendelian randomization approach, we assessed the genetic predictive causality between thousands of proteins and AF risk and found that genetically predicted plasma levels of phosphomevalonate kinase, tumor necrosis factor ligand superfamily member 12, sulfhydryl oxidase 2, interleukin‐6 receptor subunit alpha, and low‐affinity immunoglobulin gamma Fc region receptor II‐b might decrease AF risk, while genetically predicted plasma levels of beta‐mannosidase, collagen alpha‐1(XV) chain, ANXA4 (annexin A4), COF2 (cofilin‐2), and RAB1A (Ras‐related protein Rab‐1A) might increase AF risk (P<3.4×10(−5)). By using different Mendelian randomization methods and instrumental variable selection thresholds, we performed sensitivity analyses in 30 scenarios to test the robustness of positive findings. Replication analyses were also performed in independent samples to further avoid false‐positive findings. Drugs targeting tumor necrosis factor ligand superfamily member 12, interleukin‐6 receptor subunit alpha, low‐affinity immunoglobulin gamma Fc region receptor II‐b, and annexin A4 are approved or in development. The results of the phenome‐wide Mendelian randomization analysis showed that changing the plasma levels of phosphomevalonate kinase, cofilin‐2, annexin A4, Ras‐related protein Rab‐1A, sulfhydryl oxidase 2, and collagen alpha‐1(XV) chain did not increase the risk of other diseases while decreasing the risk of AF. CONCLUSIONS: We found a significant causal association between genetically predicted levels of 10 plasma proteins and AF risk. Four of these proteins have drugs targeting them that are approved or in development, and our results suggest the potential for these drugs to treat AF or cause AF. Sulfhydryl oxidase 2, low‐affinity immunoglobulin gamma Fc region receptor II‐b, and beta‐mannosidase have not been suggested by previous laboratory or epidemiological studies to be associated with AF and may reveal new pathophysiological pathways as well as therapeutic targets for AF.